| Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same -> Monitor Keywords |
|
|
 
Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of sameRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, In Vivo Diagnosis Or In Vivo Testing, Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.)Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20070092448, Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same. Brief Patent Description - Full Patent Description - Patent Application Claims
TECHNICAL FIELD [0001] The present invention relates to: inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte, and utilization of same. Particularly, the present invention relates to: a screening method and an atopic dermatitis-like symptom inducing method preferably applicable to analysis of pathogenic mechanisms of atopic dermatitis and atopic dermatitis-like symptoms, and to development of therapeutic drugs thereof; and usages of the methods. BACKGROUND ART [0002] Skin is the largest organ in a body, and a forefront for defending a living-organism. Epidermis consists of keratinocytes (KC), melanocytes, epidermis Langerhans cells (LC), intraepithelial T cells, and the like. [0003] LC are immature dendritic cells (DC), whose function is to capture and transport locally exposed protein antigen to draining lymph nodes in which acquired immune responses are generally accomplished. During their migration to a lymph node, LC develop into mature DC having antigen-presenting capacity. As a result, a systemic immune response specific to the antigen carried by the LC/DC is caused. In this way, the antigen-specific immune response in the skin is closely associated with the systemic immune response to the same antigen. Therefore, it is thought that skin and immune organs are tightly connected with each other via circulatory trooping of LC/DC and via antigen specific immune cells. On the other hand, KC and melanocytes reside in the skin, and do not principally participate in an acquired immune response. [0004] However, KC might contribute to development of local innate immune response and local inflammation. When microbes infect skin, a host develops an inflammation reaction, and then develops an acquired immune reaction in a manner localized in the skin. At that time, KC and LC constituting the skin are closely involved in each reaction. Therefore, it is thought that, based on their unique property of producing various cytokines upon stimulation from microbes or chemical reagents, KC has a large influence on LC, with a result that KC modify an acquired immune response (see Non-Patent Documents 1 and 2). In consideration of these facts, it is important to determine whether KC-induced cutaneous inflammation can also affect the systemic immune response. [0005] The inventor of the present invention have established caspase-1 transgenic mice (KCASP1Tg mice) which KC-specifically express caspase-1, and develop atopic dermatitis (AD)-like inflammatory skin lesions (pruritic chronic inflammation) in an interleukin 18 (IL-18)- and interleukin 1.beta. (IL-1.beta.)-dependent manner (see Non-Patent Documents 3 and 4). Further, the inventor of the present invention has disclosed that IL-1.beta. enhances the capacity of IL-18 to induce AD-like inflammatory skin lesions (see Non-Patent Document 4). These results suggest that KC may also contribute to the systemic immune response by producing a number of cytokines including IL-18 and IL-1.beta.. [0006] The IL-18 and IL-1.beta. are produced as biologically inert precursors, and are released as an active form after being cleaved by appropriate intracellular enzymes such as caspase-1 (see Non-Patent Documents 5 through 9). [0007] The IL-18 has diverse biological actions depending on the kinds of cytokines coexisting with the IL-18. Particularly, in the presence of interleukin 12 (IL-12), IL-18 promotes inflammatory responses via induction of IFN-.gamma. which is a potent pro-inflammatory cytokine (see Non-Patent Document 10). On the other hand, in the absence of IL-12, IL-18 induces atopic response via induction of production of Th2 cytokine (see Non-Patent Document 11 through 14). [0008] The AD is an inflammatory skin lesion in response to external stimulation, and is accompanied by chronic and repetitive strong itch. The onset of the AD has a genetic basis, and a patient of the AD has high serum levels of IgE. However, the pathogenic mechanism of the AD is poorly understood. Activated T cells, basophil, and mast cells are closely involved in the pathogenic mechanism of the AD. [0009] Particularly, it is thought that as a result of activation of mast cells or basophil by an allergen, Th2 cytokines and chemical mediators are produced, and accordingly AD is developed. The activation of mast cells or basophil by allergen is caused by crosslinking of IgE molecule bound to Fc .epsilon. R (Fc receptor (FcR) to IgE antibody of basophil) on these cells. Important ones out of the Th 2 cytokines are, for example, interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 9 (IL-9), and interleukin 13 (IL-13). Important ones out of the chemical mediators are, for example, histamine, serotonin, and leukotriene. [0010] It is known that infection of. Staphylococcus aureus exacerbates inflammation of skin of an AD patient according to environments (see Non-Patent Documents 15 and 16), and increases density of serum IL-18 of some AD patients (see Non-Patent Document 17). Namely, it is known that the infection of Staphylococcus aureus is an inducing factor or exacerbation factor of AD. However, it is poorly known how Staphylococcus aureus is involved in the onset of AD. [Non-Patent Document 1] [0011] Jamora, C. and Fuchs, E. 2002. Intercellular adhesion, signaling and the cytoskeleton. Nat. Cell Biol. 4:E101 [Non-Patent Document 2] [0012] Grone, A. 2002. Keratinocyte and cytokine. Vet. Immunol. Immunopathol. 88:1. [Non-Patent Document 3] [0013] Yamanaka, K., Tanaka, M., Tsutsui, H., Kupper, T. S., Asahi, K., Okamura, H., Nakanishi, K., Suzuki, M., Kayagaki, N., Black, R. A., et al. 2000. Skin-specific caspase-1 transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J. Immunol. 165:997. [Non-Patent Document 4] [0014] Konishi, H., Tsutsui, H., Murakami, T., Yumikura-Futatsugi, S., Yamanaka, K., Tanaka, M., Iwakura, Y., Suzuki, N., Takeda, K., Akira, S., Nakanishi, K., and Mizutani, H. 2002. IL-18 contributes to the spontaneous development of an atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA. 99:11340. [Non-Patent Document 5] [0015] Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M. A., Hayashi, N., Higashino, K., Okamura, H., Nakanishi, K., et al. 1997. Activation of interferon-.gamma. inducing factor mediate by interleukin-1.beta. converting enzyme. Science 275:206. [Non-Patent Document 6] [0016] Tsutsui, H., Kayagaki, N., Kuida, K., Nakano, H., Hayashi, N., Takeda, K., Matsui. K., Kashiwamura, S., Hada, T., Akira, S., et al. 1999. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 11:359. Continue reading about Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same... Full patent description for Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same or other areas of interest. ### Previous Patent Application: Patient selection method for assisting weight loss Next Patent Application: Methods for direct visualization of active synapses Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same patent info. IP-related news and info Results in 1.1857 seconds Other interesting Feshpatents.com categories: Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
